何山杉Melissa He Ph.D.

律师

圣地亚哥 + 1.858.314.1154

联系：

Share

何山杉博士协助客户在制药、生物技术和化学等领域申请专利并管理全球专利池方面的工作。她的执业内容包括全球专利池的开发与管理、尽职调查、可专利性和有效性评估、自由实施分析及专利战略咨询等。

Melissa 富有经验的领域包括免疫疗法（如单特异性抗体和多特异性抗体）、基因疗法（如基于mRNA的、病毒或非病毒载体疗法）、细胞疗法（如CAR-T 和CAR-NK 治疗）、脂质纳米粒、生物标记与诊断，以及小分子制药等。Melissa 曾参与的小分子制药案例涉及REVLIMID® 、iberdomide、mezigdomide等小分子。

她代理的客户包括艾伯维（AbbVie）、 默克 (Merck) 和 BMS/Celgene，以及其他初创公司、成熟公司、学术机构和投资公司。

Melissa在专利诉讼和专利授权后重审程序方面也具有丰富经验，包括在专利审查与上诉委员会 (PTAB) 进行的多方复审。

加入众达前，Melissa曾在某国际律所的专利诉讼团队工作三年多，并曾担任10余年的科学家。Melissa是多项专利申请的共同发明人并且作为第一作者曾在《科学转化医学》（Science Translational Medicine）和《药物化学杂志》（Journal of Medicinal Chemistry）等期刊中发表过多篇科研论文。她发表的文章被评为《自然综述：药物发现》（Nature Reviews Drug Discovery）的“研究亮点”并入选美国化学学会精选文献（American Chemical Society Editors' Choice）。

经验

  • METiS Pharmaceuticals develops global patent portfolios related to lipid nanoparticles for mRNA-based gene therapiesJones Day is representing METiS Pharmaceuticals, Inc. in connection with the establishment of global patent portfolios related to lipid nanoparticles (LNP) and uses thereof in various mRNA-based gene therapies.
  • AbbVie develops patent portfolio related to adalimumab formulationsJones Day is representing AbbVie Inc. in connection with the development of global patent portfolios related to formulations for AbbVie's antibody adalimumab, marketed as HUMIRA®.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
    •

    • January 18, 2024
      Foreign Filing Licenses and Other Issues Related to Cross-pacific Patent Inventions

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice